Correct usage and recommended dosage of Inavolisib

Inavolisib (Inavolisib) is a new generation of selective PI3Kα inhibitor. Its clinical positioning is highly dependent on gene mutation characteristics. Therefore, PIK3CA gene testing before officially starting treatment is a key step to ensure precise medication. For HR -positive, HER2 -negative breast cancer patients who have developed locally advanced or metastatic disease, if one or more PIK3CA mutations are clearly present in plasma samples or tumor tissues, they are eligible for targeted therapy with inaliset.

Based on the correlation between the PI3K pathway and metabolic regulation, the guidelines generally emphasize the assessment of fasting blood glucose, random blood glucose and HbA1c before medication, and maintain dynamic monitoring during treatment to detect metabolic changes early and reduce the risk of adverse reactions to hyperglycemia caused by drugs. Many overseas breast cancer centers also emphasize that lifestyle intervention and glucose metabolism optimization before starting treatment can help improve tolerance.

In terms of the recommended dose, the standard usage of inalised is 9mg taken orally once a day, which can be taken with food or on an empty stomach, and it is emphasized to maintain a regular time point. Tablets must be swallowed whole and not crushed or divided to ensure that the sustained-release properties of the drug are not destroyed and to avoid changes in pharmacokinetics. If the patient forgets to take the medicine on a certain day, he only needs to take it within 9 hours of the scheduled time; but if it exceeds this time window, he should skip it directly and continue taking the medicine according to the scheduled plan from the next time. It is not recommended to take additional medicine to avoid dose superposition. If vomiting occurs after taking the medicine, there is no need to take another dose on the same day. This is a safety strategy commonly adopted internationally. Long-term regular administration can help maintain the stability of PI3Kα inhibitory effect, thereby prolonging disease control time.

In actual clinical treatment scenarios, inalised is often used in combination with palbociclib and fulvestrant, which is a common combination in international breast cancer treatment strategies. In this combination, the recommended dose of palbociclib is 125 mg once daily, taken " 21 days + 7day pause” cyclical pattern, while fulvestrant is administered as a fixed-dose injection according to specific guidelines. Such a combined strategy aims to synergistically inhibit tumor cell proliferation through multiple pathways and improve the ability to fight endocrine drug resistance. Overseas experts emphasized that the advantage of the combined approach is that it can block multiple key nodes at the same time, thereby achieving a more stable long-term treatment effect.

During long-term treatment, the management of side effects of inalise also needs to be standardized. For example, possible increases in blood sugar, skin reactions, gastrointestinal discomfort, etc. can all be dealt with through dynamic monitoring and diet adjustment. Some patients may need to work with endocrinologists to manage blood sugar, while patients with poor skin tolerance are advised to moisturize and protect their skin from the sun at an early stage to reduce irritating factors. If intolerable adverse reactions occur during treatment, you should communicate with your doctor in a timely manner, and the clinical team will evaluate whether you need to temporarily discontinue the drug or reduce the dose.

Taken together, as a new targeted drug for PIK3CA mutated breast cancer, its correct usage not only follows the 9mg oral dosage principle, but also emphasizes individualized management, metabolic monitoring, and a combination strategy with CDK4/6 inhibitors and endocrine therapy.

Reference materials: https://www.itovebi-hcp.com/